Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...
Gene therapy revolutionizes retinal disease treatment, offering long-lasting solutions and reducing the need for frequent injections in patients with nAMD. Over the past decade, intravitreal ...
For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice. In this installment, ...
The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD. Outlook Therapeutics, Inc. reported ...
Aaron Nagiel, MD, PhD, gave an interview discussing the work that he and the team at Children’s Hospital Los Angeles (CHLA) have been doing in the retinal gene therapy space. This interview comes at ...
Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...
At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs). At the Retina World Congress 2025 in Lauderdale, ...
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
As part of the Johns Hopkins Wilmer Eye Institute’s MACULA 2025 and the 5th Annual Retina Festival, Christina Y. Weng, MD, MBA, gave a presentation titled “Home Monitoring for Age-Related Macular ...
The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the ...
This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...
MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52. The 2-year Phase 2b RESTORE trial has achieved its primary and key secondary endpoints ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback